KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Common Equity (2016 - 2025)

Historic Common Equity for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $836.6 million.

  • Neogenomics' Common Equity fell 728.96% to $836.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $836.6 million, marking a year-over-year decrease of 728.96%. This contributed to the annual value of $836.6 million for FY2025, which is 728.96% down from last year.
  • Per Neogenomics' latest filing, its Common Equity stood at $836.6 million for Q4 2025, which was down 728.96% from $838.3 million recorded in Q3 2025.
  • Neogenomics' 5-year Common Equity high stood at $1.1 billion for Q2 2021, and its period low was $836.6 million during Q4 2025.
  • Its 5-year average for Common Equity is $962.7 million, with a median of $944.5 million in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 7552.84% in 2021, then crashed by 1092.61% in 2022.
  • Neogenomics' Common Equity (Quarter) stood at $1.1 billion in 2021, then decreased by 9.95% to $998.0 million in 2022, then decreased by 5.66% to $941.5 million in 2023, then dropped by 4.16% to $902.3 million in 2024, then decreased by 7.29% to $836.6 million in 2025.
  • Its Common Equity stands at $836.6 million for Q4 2025, versus $838.3 million for Q3 2025 and $854.0 million for Q2 2025.